Amazed2 Sep 2020 12:06
We are not trading at multiples of the current SP.
The LSTM have been assessing the LFT performance for almost 1 month, so it can be considered a FACT that our CEO knows exactly what the clinical performance looks like.
For our CEO to state in todays RNS, "we are confident of meeting and exceeding the clinical performance requirements for identifying the most infectious people" says all we need to know.
Also, it is worth re-reading the LSTM RNS;
Under the terms of the collaboration, LSTM will carry out the clinical validation of the Avacta COVID-19 antigen rapid saliva test in their category 3 laboratories on patient samples. In addition to working with the UK government's CONDOR programme to provide Avacta with access to patient samples in the UK, the partnership with LSTM also provides the opportunity to access patient samples in Africa and South America. The higher prevalence of the disease in those regions means that samples for prospective clinical validation studies are more readily available which, if necessary, could be used to speed up the validation process.
Clinical validation is the process of evaluating the performance of a diagnostic test using real patient samples. Clinical validation generates the sensitivity and specificity performance parameters which are most often used to define the performance of a diagnostic test.
LSTM is currently evaluating the performance of prototype lateral flow tests provided by Cytiva alongside Avacta's ELISA laboratory test using SARS-CoV-2 coronavirus samples, as a precursor to full clinical validation studies.
Sign In
Follow the stocks
